Just about every day to every other day there are negative plagiarized articles by either the Street, Zacks or the M F ers. They keep on posting their same OLD ARTICLES over and over again. These P&D's need to get a life.
These guys cannot do research on their own; they have to copy (plagiarize) other sources of information and rearrange the wording as if it were their article.
I am guessing that the Street and Motley Fool are both paid bashers.
Here's a Reason Why Valeant (VRX) Stock Is Down Today
Above from The Street (TST) with a sell on VRX.
These numnuts have no idea on what stock is a buy or a sell… they are clueless.
Check out the stock performance for TST:
I rate TST A STRONG SELL!!!!
with their same old articles. There is absolutely nothing new in their article.... all old stuff.
Ackman did say that was not going to sell assets apparently he changed his mind.
Sentiment: Strong Buy
… a few times a month on Valeant. Cramer how are you still able to operate your TST website that no one subscribes too? Your comments are useless.
Your stock price has been flat lined for years.
Chanos is back today REITERATING his short position this time on the rag Investopida site. Getting a little tired of Chanos REITERATING his short WEEKLY position. The man is getting desperate. Give it up Chanos!!!
The prescriptions for the company showed signs of recovery after 7 weeks of continuous declines
Published By: Patrick Arruda on May 6, 2016 11:39 am EST
Valeant Pharmaceuticals Intl Inc. (NYSE:VRX) is starting to gain some momentum as the company’s prescriptions showed some growth during the week ending 29th of April. The prescriptions have been on a continual decline for the past few weeks. Derm, Ophth and Addyi all showed growth in the number of new prescriptions during the week with Addyi outpacing the other two with a growth of 16.2% week over week.
Douglas Miehm Analyst at RBC Capital sees the return to growth as a positive but refrains from making any lofty assumptions as it might very well be temporary. The analyst noted that the new prescriptions for Derm franchise rose by 2.2% during the week, compared to 2.9% decline in the prior. The total number of new prescriptions during the week were 53,803 ahead of 52,603 new prescriptions during the prior week. Total prescriptions for Derm also grew by 2.2% recovering from 2% decline during the week ending 22nd April. Total prescriptions during the week were 72,206, while, the total prescriptions for the week prior amounted to 70,622.
There was more to the article, just do a google search.
From S&P dtd. 4/30/16
S&P has VRX with 4-stars
Our 12-month target of $90 is based on below peers 9X our 2016 EPS estimate, on continued volatility and uncertainty.
It sounds like it’s going to be a bumpy ride!